ScreenerHero

SRNE Sorrento Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · sorrentotherapeutics.com
0.0004USD0.00%Mkt Cap: 220512 $P/E: —

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap220.51K USD
Enterprise Value134.56M USD
Revenue (TTM)64.27M USD
Gross Profit29.39M USD
Net Income (TTM)-572.84M USD
Revenue/Share0.13 USD
Last Price0.0004 USD
Fiscal Year EndDec 2022
MR QuarterJun 2023
Employees949
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.39
EV/Revenue2.09
P/S0.01
P/B-0.00
EPS (TTM)-1.79
EPS (Forward)—
52W Range
0.00010% of range0.0733
52W High0.0733 USD
52W Low0.0001 USD
Profitability
Gross Margin46.77%
Oper. Margin-510.93%
EBITDA Margin0.00%
Profit Margin-911.60%
ROE3078.97%
ROA-121.15%
Growth
Revenue Growth31.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-293.86M USD
CapEx (TTM)13.66M USD
FCF Margin-89.51%
FCF Yield-26089.06%
Net Debt126.97M USD
Net Debt/EBITDA-0.37
Balance Sheet
Debt/Equity-7.23
Current Ratio0.41
Quick Ratio0.34
Book Value/Sh-0.38 USD
Cash/Share0.15 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateAug 1, 2013
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.551.28M
Float539.11M
Insiders0.00%
Institutions0.04%
Short Interest
Short Ratio5.0d
Short % Float11.96%
Short % Out.11.84%
Shares Short64.56M
Short (prev mo.)61.44M
Technical
SMA 500.0006 (-33.3%)
SMA 2000.0015 (-74.1%)
Beta-0.01
S&P 52W Chg16.45%
Avg Vol (30d)99.84K
Avg Vol (10d)79.03K
Technical Indicators
RSI (14)40.6
MACD-0.0001
MACD Signal-0.0001
MACD Hist.-0.0000
BB Upper0.0009 USD
BB Middle0.0006 USD
BB Lower0.0003 USD
BB Width102.08%
ATR (14)0.0011 USD
Vol Ratio (20d)0.35x